Early pregnancy loss (EPL) is a common complication in pregnancy and affects approximately
1 million women in the United States every year [
[1]
,
[2]
]. Patient-centered care includes expectant, medical and procedural treatment options.
Medical management offers an expedient and active treatment course that is less invasive
and more private than uterine aspiration [
3
,
4
,
5
,
6
,
7
], and misoprostol alone has traditionally been used for medical management of EPL.
However, treatment efficacy is substantially improved when mifepristone is used as
a pretreatment to misoprostol [
8
,
9
,
10
,
11
,
12
]. Additionally, cost-effectiveness analyses demonstrate that the combination regimen
has economic benefits for both patients and the health care sector [
[13]
,
[14]
]. Based on these pivotal studies and the American College of Obstetrics and Gynecology
(ACOG) recommendations, the combined mifepristone-misoprostol regimen has become the
standard of care for medical management of EPL [
[8]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Spontaneous abortion risks in man: data from reproductive histories collected in a medical genetics unit.Am J Hum Genet. 1964; 16: 1-25
- Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008.Natl Vital Stat Rep. 2012; 60: 1-21
- A comparison of medical management with misoprostol and surgical management for early pregnancy failure.N Engl J Med. 2005; 353: 761-769
- Clinical indicators for success of misoprostol treatment after early pregnancy failure.Int J Gynaecol Obstet. 2007; 99: 46-51
- Mifepristone and misoprostol for the treatment of early pregnancy failure: a pilot clinical trial.Contraception. 2006; 74: 458-462
- Mifepristone and misoprostol for early pregnancy failure: a cohort analysis.Am J Obstet Gynecol. 2011; 204 (p. 386 e1-386 e6)
- Treatment decisions at the time of miscarriage diagnosis.Obstet Gynecol. 2016; 128: 1347-1356
- Practice Bulletin No. 200 summary: early pregnancy loss.Obstet Gynecol. 2018; 132: 1311-1313
- Medical treatment for early fetal death (less than 24 weeks).Cochrane Database Syst Rev. 2019; 6CD002253
- Management of first-trimester miscarriage: a systematic review and network meta-analysis.Hum Reprod Update. 2019; 25: 362-374
- Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial.Lancet. 2020; 396: 770-778
- Mifepristone pretreatment for the medical management of early pregnancy loss.N Engl J Med. 2018; 378: 2161-2170
- Cost-effectiveness of mifepristone pretreatment for the medical management of nonviable early pregnancy: secondary analysis of a randomized clinical trial.JAMA Netw Open. 2020; 3e201594
- Mifepristone combination therapy compared with misoprostol monotherapy for the management of miscarriage: a cost-effectiveness analysis.Obstet Gynecol. 2020; 136: 774-781
- Slow implementation of mifepristone medical termination of pregnancy in Quebec, Canada: a qualitative investigation.Eur J Contracept Reprod Health Care. 2020; 25: 190-198
- Life cycle of translational research for medical interventions.Medicine. 2008; 321 (Science): 1298-1299
- Time to reevaluate U.S. mifepristone restrictions.N Engl J Med. 2019; 381: 597-598
- Aligning mifepristone regulation with evidence: driving policy change using 15 years of excellent safety data.Contraception. 2015; 92: 179-181
ACOG. Improving access to mifepristone for reproductive health indications. 2018; Posiiton Statement].
- United States emergency department visits for vaginal bleeding during early pregnancy, 1993-2003.Am J Obstet Gynecol. 2008; 198 (p. 523 e1-6)
- Patient experiences with miscarriage management in the emergency and ambulatory settings.Obstet Gynecol. 2019; 134: 1285-1292
- Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis.EClinicalMedicine. 2020; 29100630
- Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: a nationwide cohort study.PLoS Med. 2020; 17e1003379
FDA, Guidance for Industry and Health Care Professionals: Policy for Certain REMS requirements during the COVID-19 Public Health Emergency. https://www.fda.gov/media/136317/download.
ACLU, Federal court blocks FDA restsriction that unnecessarily imposes COVID-19 risks on patients seeking abortion care 2020: https://www.aclu.org/press-releases/federal-court-blocks-fda-restriction-unnecessarily-imposes-covid-19-risks-patients#:~:text=The%20court%20issued%20a%20preliminary,as%20part%20of%20miscarriage%20treatment.
- Supreme Court Revives Abortion-Pill Restriction.The New York Times, 2021
Belluck, P., F.D.A. Will Allow Abortion Pills by Mail During the Pandemic, in The New York Times. 2021.
Berry, C.R. The dividing line between the role of the FDA and the practice of medicine: a historical review and current analysis. 1997. http://nrs.harvard.edu/urn-3:HUL.InstRepos:8846812
Article info
Publication history
Published online: April 22, 2021
Accepted:
April 9,
2021
Received in revised form:
April 8,
2021
Received:
January 27,
2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
